CANADA LIFE ASSURANCE Co Purchases 4,110 Shares of United Therapeutics Co. (NASDAQ:UTHR)

CANADA LIFE ASSURANCE Co increased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,389 shares of the biotechnology company's stock after acquiring an additional 4,110 shares during the period. CANADA LIFE ASSURANCE Co owned approximately 0.16% of United Therapeutics worth $24,800,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter worth $25,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics in the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB boosted its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Anchor Investment Management LLC grew its stake in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Stock Up 0.2 %

UTHR stock traded up $0.64 during trading hours on Wednesday, hitting $293.46. The company's stock had a trading volume of 225,287 shares, compared to its average volume of 450,218. The company has a market capitalization of $13.18 billion, a PE ratio of 12.89, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The stock has a 50 day moving average price of $313.33 and a two-hundred day moving average price of $347.74. United Therapeutics Co. has a 12 month low of $233.28 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. During the same quarter in the previous year, the firm earned $4.36 earnings per share. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on UTHR shares. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target on the stock in a research report on Monday. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a report on Monday. Finally, UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $395.67.

Insider Activity

In other news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $10,437,712.18. This trade represents a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Raymond Dwek sold 3,000 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $285.57, for a total transaction of $856,710.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at $499,747.50. This trade represents a 63.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,500 shares of company stock valued at $28,179,150 over the last 90 days. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.